WIM
BPMC

Waverton Investment Management’s Blueprint Medicines BPMC Stock Holding History

Waverton Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14,760
Closed -$1.11M – 76
2017
Q4 		$1.11M Buy
14,760
+2,260
+18% +$159K 0.07% 49
2017
Q3 		$871K Hold
12,500
– – 0.05% 54
2017
Q2 		$633K Buy
+12,500
New +$531K 0.04% 68

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Waverton Investment Management's BPMC Position: Q1 2018 in Review

Waverton Investment Management sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 14,760 shares — an estimated $1.11M sold.

Waverton Investment Management first reported a position in BPMC in Q2 2017 and held it in 3 quarters. The position peaked at $1.11M in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

  • Waverton Investment Management reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
  • Waverton Investment Management sold 14,760 Blueprint Medicines shares in Q1 2018, an estimated $1.11M.
  • Waverton Investment Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 3 quarters.
  • Waverton Investment Management's Blueprint Medicines position peaked at $1.11M in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on Waverton Investment Management's 13F filing for Q1 2018, filed 6 Apr 2018.